Leen Khaled AlAngari

Ms. Leen Khaled AlAngari

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Ghaith K. MansourGhaith K. Mansour
Ghaith K. Mansour
LALeen Khaled AlAngari
Leen Khaled AlAngari
LKLeen Khosyfan
Leen Khosyfan
RAReem Alhammad
Reem Alhammad
AHAhmad W. Hajjar
Ahmad W. Hajjar
Efgartigimod is a novel neonatal Fc receptor (FcRn) antagonist that reduces pathogenic immunoglobulin G (IgG) autoantibodies, offering a targeted therapeutic approach for generalized myasthenia gravis (gMG) and other antibody-mediated autoimmune diseases. This narrative review synthesizes clinical trial data, pharmacological insights, and real-world evidence to evaluate efgartigimod’s efficacy, safety, and emerging applications. Phase 3 randomized controlled trials and extension studies demonstrate rapid and sustained improvements in muscle strength and patient-reported outcomes with a favorable safety profile, including reduced reliance on corticosteroids and intravenous immunoglobulin (IVIg). Additionally, observational studies highlight its expanding utility in diverse IgG-mediated disorders such as immune thrombocytopenia (ITP) and autoimmune encephalitis. Efgartigimod thus represents a paradigm shift in autoimmune disease management, enabling precision immunomodulation with the potential for broad clinical impact and improved patient quality of life (QOL).

7 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Ghaith K. MansourGhaith K. Mansour
Ghaith K. Mansour
LALeen Khaled AlAngari
Leen Khaled AlAngari
LKLeen Khosyfan
Leen Khosyfan
RAReem Alhammad
Reem Alhammad
AHAhmad W. Hajjar
Ahmad W. Hajjar
Efgartigimod is a novel neonatal Fc receptor (FcRn) antagonist that reduces pathogenic IgG autoantibodies, offering a targeted therapeutic approach for generalized myasthenia gravis (gMG) and other antibody-mediated autoimmune diseases. This narrative review synthesizes clinical trial data, pharmacological insights, and real-world evidence to evaluate efgartigimod's efficacy, safety, and emerging applications. Phase 3 randomized controlled trials and extension studies demonstrate rapid and sustained improvements in muscle strength and patient-reported outcomes with a favorable safety profile, including reduced reliance on corticosteroids and intravenous immunoglobulin. Additionally, observational studies highlight its expanding utility in diverse IgG-mediated disorders such as immune thrombocytopenia and autoimmune encephalitis. Efgartigimod thus represents a paradigm shift in autoimmune disease management, enabling precision immunomodulation with the potential for broad clinical impact and improved patient quality of life (QOL).